Antacids Market

Antacids Market (Drug Class - Proton Pump Inhibitor, H2 Antagonist, and Acid Neutralizers; Formulation Type - Tablet, Liquid, and Powder; Distribution Channel - Hospital Pharmacies and Retail Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Sedentary and Stressed Lifestyle Necessitates Demand for Antacids

According to the data revealed by the Population Reference Bureau (PRB), the genarian population across the world is expected to reach 16% from 9%  in 2018. As these people are more susceptible to weak digestion and stomach related issues due to low immunity, they are the important consumers of antacids. With the advancement in medical technology, there has been a rise in life expectancy in people, which leads to an increased number of the elderly population. Based on WHO statistics, the global life expectancy in 2016 was 72 years average, with 74.2 years in women and 69.8 years in men. Owing to improvement in sanitation, vaccination, and so on, the number of mid and early-life mortality is foreseen to decrease to a large extent. This fortifies the usage of antacids by the elderly population, stimulating the demand in global antacids market.

Besides this, the consumption of antacids has also increased due to a number of people relying on ready-to-eat foods due to a busy lifestyle. In addition, consumption of junk food which has certain preservatives responsible for disturbing the digestion, and chemicals triggering heartburn is another factor that encouraged Transparency market Research to come up with a report on antacids market. Lack of physical activities leading to obesity and chronic gastrointestinal disorders are additionally fortifying the motive behind presenting this report for the clients and investors for detailed analysis. The report highlights all the leading factors and trends in antacids market, along with certain drawbacks which should be considered before investment. It also unveils the important market figures depicting the current and upcoming market scenario.

.

antacids market

Researchers Working on Developing More Instantly Effective and Long Lasting Antacids

Around two decades ago, proton pump inhibitors (PPIs) were among the most preferred drugs to treat patients suffering from chronic acidity. But, these agents still lacked the efficiency to treat acidity completely, as they did not possess accuracy in several aspects. Earlier, the PPIs, named (lansoprazole, omeprazole, and pantoprazole worked well for showing immediate relief from stomach-related issues. However, they were inefficient in treating acid-related issues for a long time. The advanced proton pump inhibitors drugs, esomeprazole, and rabeprazole, are more reliable and effective. These are known to have a greater and long-lasting effect during evening after 5 days of administration.. These new antacid drugs with PPI agents have several advantages in managing gastro-esophageal reflux disease (GERD). In addition, growing awareness about these disorders is adding to the demand in antacids market.

Proton pump inhibitors accounted for a whopping 66.4% revenue in 2016, leading the global antacids market. The consistent growth in revenue is expected to sustain its dominance in the coming years as well, owing to several developments coming its way. Looking at this, the global antacids market is prognosticated to expand at a CAGR of 4.1% during the forecast period from 2017 to 2025. In market was valued around worth of US$9,050 mn in 2016, which is likely to reach around US$12,857.3 mn. Looking at the figures, the players willing to invest as well as the existing ones are likely to have a huge scope of growth in the coming years. With an amount ~US$3,806.7 mn the global antacids market is expected to provide a significant incremental value for the key players in the market.

Reliability on Digestive Remedies Due to Low Physical Activity to Uplift Market Growth

Some of the leading factors responsible for the rising consumption of antacids are leisure habits, sedentary lifestyle, poor diets, obesity, and increasing stress in daily life. These aspects are known to have a detrimental effect on the digestive system and its functioning. Because of this, the consumers are relying on several digestive remedies, such as antacids. Additionally, there has been a major shift ] from prescribed drug to OTC drugs, in the pharmaceutical sector. Thus, the antacid drugs can be purchased over-the-counter, and are available at affordable price in various flavors. Some of the OTC drugs are Gelusil, Alka-Seltzer, and Pepto-Bismol. According to a study, the global antacids market grows by US$10 bn every years. The rising prevalence of GERD, heartburn, and acidity since a while, there is a growth in North America from 18% to 28%, among which 25% are adults complaining for acidity and heartburns regularly.

Consumption of Aluminum-Based Antacids to Have No Indications of Dementia

Lately, the intake of aluminum-based antacid was consumed without the fear of suffering from dementia. The amount of aluminum in antacids is extremely small, and a body has its own ways of excreting that negligible amount, without harming the function of any organ, and making it toxic.

A few years ago, concerns were raised against consumption of PPIs for a long duration. However, recently, a study fortified that the intake of proton pump inhibitors is not associated with mortality rate, as stated in other studies earlier. With PPIs claimed to be safe for consumption, the global antacids market finds another factor in its current situation.

According to a recent study published by Nature Communications journal, intake of drugs prescribed for treating heartburn could result in allergies in some people. Researchers studied the people prescribed with drugs such as H2 blockers and PPIs, who were also recommended to have an anti-allergy medicine. The study said that allergy might pop-up after few years after consumption of gastric acid inhibitors. Eight million people were kept under observation for this research.

Home Remedies for Acidity Related Issues to Have Reverse Impact on Market Growth

However, on the flipside, home remedies for occasional heartburns and acidity, and change in eating habits and lifestyle are some of the other alternatives posing a threat to global antacids market. Moreover, awareness about herbal medicines and traditional methods are also among the restrictive factors in the market growth.

Astudy published by Gut journal stated that young children who were prescribed drugs to reduce stomach acid, showed symptoms of obesity. Prolonged consumption of acid-related medicines tend to alter gut microbes resulting in weight gain.

Another study has showed the link between prescribing antacids to infants and bone fractures. Acid suppressants given to babies below the age of 1 year, resulted in 23% chances of fracture when consumed PPIs, and a huge 31% chances when PPIs and H2 blockers, both were prescribed. Having said that, there are other factors influencing the cause of fracture such as child being overweight, gender, and pre-mature birth, to state the least.

Growth in Online Pharmacy in Europe to Make it a Leading Region

The global antacids market was led by Europe by 36.9% share in 2016. The regional market is anticipated to witness a steep growth graph in coming years as well with a CAGR of 3.2% within the forecast period from 2017 to 2025, with an expected valuation of ~ US$6647.4 mn. This dominance is attributed to increasing cases of gastrointestinal diseases in the region, along with advanced facilities for therapeutics and diagnosis. As a result the region holds a huge demand and availability of antacids as over-the-counter drugs in several brand stores. Growth in online pharmacy and rise in e-commerce sector is another fueling factor behind the growth in Europe antacids market, resultantly fulfilling global demand.

In addition, the region is a home for many leading companies in global antacids market such as Bayer AG, AstraZenca, Boehringer Ingelheim GmbH, GlaxoSmithKline plc., and Sanofi. According to the analyst at TMR, these companies are majorly focusing on strategies like mergers and acquisitions and product development. In March 2015, AstraZeneca got into agreement with a company in the US, Daiichi Sankyo, Inc. for Movantik, which is an oral, once-a-day, peripherally-acting mu-opioid receptorantagonist (PAMORA) used for treating opioid-induced constipation (OIC). This has resulted in improved revenue for both the companies.

Similarly, GlaxoSmithKline in February 2015, took over GlycoVaxyn AG, headquartered at Switzerland, which is a specialist vaccine biopharmaceutical firm, to take ahead itsinitial stage vaccines pipeline. The company also invested US$294.39 million in 2016, for R&D in Consumer Healthcare, for innovations, like Excedrin Gel-tabs, Eno in new ajwain flavor in India, Sensodyne True White, and so on. These launches have helped the company to increase their reach among the masses, along with new flavors which would attract the customers to buy their product.

Relaxed Regulations for OTC to Help Market Penetration Easy for Players

The global antacids market seems to be fragmented due to presence of several players across the globe. Increasing number of companies involved in manufacturing of pharmaceutical products intensifies the competition in the global antacids market. However, various regional and local players are willing to invest, owing to low production cost and easy availability of raw materials for antacids.

In addition, relaxed regulations for over-the-counter drugs is another factor attracting the players to enter in the global market. Thus, there is a moderate threat for new players to set their foot and make their presence noticed.

Apart this, the players are investing heavily in the research activities looking at the lucrative scope in the market, and also to explore the untapped regions. Owing to better healthcare funding from the governments in various regions, such as North America and better healthcare policies, the global antacids market is foreseen to develop by leaps and bounds in coming years.

Nevertheless, owing to strong foothold by the leading companies in the regional and global market, it seems to be a bit difficult for the new entrants to secure their position easily.  

The global antacids market has been segmented as follows:

by Drug Class

  • Proton pump inhibitors
  • H2 Antagonist
  • Acid neutralizers

by Formulation Type

  • Tablet
  • Liquid
  • Powder
  • Others

by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others  

by Region 

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • France
    • Germany
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East & Africa

    1. Preface
          1.1. Market Definition and Scope
          1.2. Market Segmentation
          1.3. Key Research Objectives
          1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary : Global Antacids Market

    4. Market Overview
          4.1. Introduction
                  4.1.1. Product Definition
                  4.1.2. Industry Evolution / Developments
          4.2. Overview
          4.3. Market Dynamics
                  4.3.1. Drivers
                  4.3.2. Restraints
                  4.3.3. Opportunity
          4.4. Global Antacids Market Value (US$ Mn) Forecast, 2017 - 2025
          4.5. Porter’s Five Force Analysis
          4.6. Value Chain Analysis
          4.7. Market Outlook

    5. Global Antacids Market Analysis and Forecasts, By Drug Class 
          5.1. Introduction & Definition
          5.2. Key Findings / Developments
          5.3. Key Trends
          5.4. Market Value (US$ Mn) Forecast, By Drug Class, 2017–2025
                  5.4.1. Proton pump inhibitors
                  5.4.2. H2 Antagonist
                  5.4.3. Acid neutralizers
          5.5. Market Attractiveness By Drug Class 

    6. Global Antacids Market Analysis and Forecasts, By Formulation Type 
          6.1. Introduction & Definition
          6.2. Key Findings / Developments
          6.3. Key Trends
          6.4. Market Value (US$ Mn) Forecast, By Formulation Type, 2017–2025
                  6.4.1. Tablet
                  6.4.2. Liquid
                  6.4.3. Powder
                  6.4.4. Others
          6.5. Market Attractiveness By Formulation Type 

    7. Global Antacids Market Analysis and Forecasts, By Distribution Channel 
          7.1. Introduction & Definition
          7.2. Key Findings / Developments
          7.3. Key Trends      
          7.4. Market Value (US$ Mn) Forecast, By Distribution Channel, 2017–2025
                  7.4.1. Hospital Pharmacies
                  7.4.2. Retail Pharmacies
                  7.4.3. Others
          7.5. Market Attractiveness By Distribution Channel 

    8. Global Antacids Market Analysis and Forecasts, By Region
          8.1. Key Findings
          8.2. Market Value (US$ Mn) Forecast, By Region, 2017-2025
                  8.2.1. North America 
                  8.2.2. Europe 
                  8.2.3. Asia Pacific 
                  8.2.4. Latin America 
                  8.2.5. Middle East and Africa 
          8.3. Market Attractiveness By Region

    9. North America Antacids Market Analysis and Forecast
          9.1. Introduction
                  9.1.1. Key Findings
                  9.1.2. Key Trends
          9.2. Market Value (US$ Mn) Forecast, By Drug Class, 2017–2025
                  9.2.1. Proton pump inhibitors
                  9.2.2. H2 Antagonist
                  9.2.3. Acid neutralizers
          9.3. Market Value (US$ Mn) Forecast, By Formulation Type, 2017–2025
                  9.3.1. Tablet
                  9.3.2. Liquid
                  9.3.3. Powder
                  9.3.4. Others
          9.4. Market Value (US$ Mn) Forecast, By Distribution Channel, 2017–2025
                  9.4.1. Hospital Pharmacies
                  9.4.2. Retail Pharmacies
                  9.4.3. Others
          9.5. Market Value (US$ Mn) Forecast, By Country, 2017–2025
                  9.5.1. U.S.
                  9.5.2. Canada
          9.6. Market Attractiveness Analysis 
                  9.6.1. By Drug Class 
                  9.6.2. By Formulation Type 
                  9.6.3. By Distribution Channel 
                  9.6.4. By Country

    10. Europe Antacids Market Analysis and Forecast
          10.1. Introduction
                  10.1.1. Key Findings
                  10.1.2. Key Trends
          10.2. Market Value (US$ Mn) Forecast, By Drug Class, 2017–2025
                  10.2.1. Proton pump inhibitors
                  10.2.2. H2 Antagonist
                  10.2.3. Acid neutralizers
          10.3. Market Value (US$ Mn) Forecast, By Formulation Type, 2017–2025
                  10.3.1. Tablet
                  10.3.2. Liquid
                  10.3.3. Powder
                  10.3.4. Others
          10.4. Market Value (US$ Mn) Forecast, By Distribution Channel, 2017–2025
                  10.4.1. Hospital Pharmacies
                  10.4.2. Retail Pharmacies
                  10.4.3. Others
          10.5. Market Value (US$ Mn) Forecast, By Country, 2017–2025
                  10.5.1. U.K.
                  10.5.2. Germany
                  10.5.3. France 
                  10.5.4. Spain
                  10.5.5. Italy
                  10.5.6. Rest of Europe
          10.6. Market Attractiveness Analysis 
                  10.6.1. By Drug Class 
                  10.6.2. By Formulation Type 
                  10.6.3. By Distribution Channel 
                  10.6.4. By Country

    11. Asia Pacific Antacids Market Analysis and Forecast
          11.1. Introduction
                  11.1.1. Key Findings
                  11.1.2. Key Trends
          11.2. Market Value (US$ Mn) Forecast, By Drug Class, 2017–2025
                  11.2.1. Proton pump inhibitors
                  11.2.2. H2 Antagonist
                  11.2.3. Acid neutralizers
          11.3. Market Value (US$ Mn) Forecast, By Formulation Type, 2017–2025
                  11.3.1. Tablet
                  11.3.2. Liquid
                  11.3.3. Powder
                  11.3.4. Others
          11.4. Market Value (US$ Mn) Forecast, By Distribution Channel, 2017–2025
                  11.4.1. Hospital Pharmacies
                  11.4.2. Retail Pharmacies
                  11.4.3. Others
          11.5. Market Value (US$ Mn) Forecast, By Country, 2017–2025
                  11.5.1. India 
                  11.5.2. China
                  11.5.3. Japan
                  11.5.4. Australia & New Zealand 
                  11.5.5. Rest of Asia Pacific
          11.6. Market Attractiveness Analysis 
                  11.6.1. By Drug Class 
                  11.6.2. By Formulation Type 
                  11.6.3. By Distribution Channel 
                  11.6.4. By Country

    12. Latin America Antacids Market Analysis and Forecast
          12.1. Introduction
                  12.1.1. Key Findings
                  12.1.2. Key Trends
          12.2. Market Value (US$ Mn) Forecast, By Drug Class, 2017–2025
                  12.2.1. Proton pump inhibitors
                  12.2.2. H2 Antagonist
                  12.2.3. Acid neutralizers
          12.3. Market Value (US$ Mn) Forecast, By Formulation Type, 2017–2025
                  12.3.1. Tablet
                  12.3.2. Liquid
                  12.3.3. Powder
                  12.3.4. Others
          12.4. Market Value (US$ Mn) Forecast, By Distribution Channel, 2017–2025
                  12.4.1. Hospital Pharmacies
                  12.4.2. Retail Pharmacies
                  12.4.3. Others
          12.5. Market Value (US$ Mn) Forecast, By Country, 2017–2025
                  12.5.1. Brazil 
                  12.5.2. Mexico 
                  12.5.3. Rest of Latin America      
          12.6. Market Attractiveness Analysis 
                  12.6.1. By Drug Class 
                  12.6.2. By Formulation Type 
                  12.6.3. By Distribution Channel 
                  12.6.4. By Country

    13. Middle East and Africa Antacids Market Analysis and Forecast
          13.1. Introduction
                  13.1.1. Key Findings
                  13.1.2. Key Trends
          13.2. Market Value (US$ Mn) Forecast, By Drug Class, 2017–2025
                  13.2.1. Proton pump inhibitors
                  13.2.2. H2 Antagonist
                  13.2.3. Acid neutralizers
          13.3. Market Value (US$ Mn) Forecast, By Formulation Type, 2017–2025
                  13.3.1. Tablet
                  13.3.2. Liquid
                  13.3.3. Powder
                  13.3.4. Others
          13.4. Market Value (US$ Mn) Forecast, By Distribution Channel, 2017–2025
                  13.4.1. Hospital Pharmacies
                  13.4.2. Retail Pharmacies
                  13.4.3. Others
          13.5. Market Value (US$ Mn) Forecast, By Country, 2017–2025
                  13.5.1. South Africa 
                  13.5.2. Saudi Arabia 
                  13.5.3. Rest of MEA
          13.6. Market Attractiveness Analysis 
                  13.6.1. By Drug Class 
                  13.6.2. By Formulation Type 
                  13.6.3. By Distribution Channel 
                  13.6.4. By Country

    14. Competition Landscape
          14.1. Market Players
          14.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
                  14.2.1. AstraZeneca
                             14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                             14.2.1.2. Business Overview
                             14.2.1.3. Product Portfolio 
                             14.2.1.4. Financial Overview 
                             14.2.1.5. SWOT Analysis 
                             14.2.1.6. Strategic overview
                  14.2.2. Bayer AG 
                             14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                             14.2.2.2. Business Overview
                             14.2.2.3. Product Portfolio 
                             14.2.2.4. Financial Overview 
                             14.2.2.5. SWOT Analysis 
                             14.2.2.6. Strategic overview
                  14.2.3. Boehringer Ingelheim GmbH
                             14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                             14.2.3.2. Business Overview
                             14.2.3.3. Product Portfolio 
                             14.2.3.4. Financial Overview 
                             14.2.3.5. SWOT Analysis 
                             14.2.3.6. Strategic overview 
                  14.2.4. Dr. Reddy’s Laboratories Ltd.
                             14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                             14.2.4.2. Business Overview
                             14.2.4.3. Product Portfolio 
                             14.2.4.4. Financial Overview 
                             14.2.4.5. SWOT Analysis 
                             14.2.4.6. Strategic overview
                  14.2.5. GlaxoSmithKline plc
                             14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                             14.2.5.2. Business Overview
                             14.2.5.3. Product Portfolio 
                             14.2.5.4. Financial Overview 
                             14.2.5.5. SWOT Analysis 
                             14.2.5.6. Strategic overview
                  14.2.6. Johnson & Johnson
                             14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                             14.2.6.2. Business Overview
                             14.2.6.3. Product Portfolio 
                             14.2.6.4. Financial Overview 
                             14.2.6.5. SWOT Analysis 
                             14.2.6.6. Strategic overview 
                  14.2.7. Pfizer Inc. 
                             14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                             14.2.7.2. Business Overview
                             14.2.7.3. Product Portfolio 
                             14.2.7.4. Financial Overview 
                             14.2.7.5. SWOT Analysis 
                             14.2.7.6. Strategic overview
                  14.2.8. Procter & Gamble
                             14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                             14.2.8.2. Business Overview
                             14.2.8.3. Product Portfolio 
                             14.2.8.4. Financial Overview 
                             14.2.8.5. SWOT Analysis 
                             14.2.8.6. Strategic overview
                  14.2.9. Reckitt Benckiser Group plc
                             14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                             14.2.9.2. Business Overview
                             14.2.9.3. Product Portfolio 
                             14.2.9.4. Financial Overview 
                             14.2.9.5. SWOT Analysis 
                             14.2.9.6. Strategic overview
                  14.2.10. Sanofi
                             14.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                             14.2.10.2. Business Overview
                             14.2.10.3. Product Portfolio 
                             14.2.10.4. Financial Overview 
                             14.2.10.5. SWOT Analysis 
                             14.2.10.6. Strategic overview
                  14.2.11. Sun Pharmaceuticals Ltd
                             14.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
                             14.2.11.2. Business Overview
                             14.2.11.3. Product Portfolio 
                             14.2.11.4. Financial Overview 
                             14.2.11.5. SWOT Analysis 
                             14.2.11.6. Strategic overview 
                  14.2.12. Takeda Pharmaceutical
                             14.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
                             14.2.12.2. Business Overview
                             14.2.12.3. Product Portfolio 
                             14.2.12.4. Financial Overview 
                             14.2.12.5. SWOT Analysis 
                             14.2.12.6. Strategic overview
                  14.2.13. Valeant Pharmaceuticals International, Inc.
                             14.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
                             14.2.13.2. Business Overview
                             14.2.13.3. Product Portfolio 
                             14.2.13.4. Financial Overview 
                             14.2.13.5. SWOT Analysis 
                             14.2.13.6. Strategic overview

    List of Tables

    Table 01: Global Antacids Market Size (US$ Mn) Forecast, By Drug Class, 2015–2025
    Table 02: Global Antacids Market Size (US$ Mn) Forecast, By Formulation Type, 2017–2025
    Table 03: Global Antacids Market Size (US$ Mn) Forecast, By Distribution Channel, 2015–2025
    Table 04: Global Antacids Market (US$ Mn) Forecast, By Region, 2015–2025
    Table 05: North America Antacids Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 06: North America Antacids Market Size (US$ Mn) Forecast, by Formulation Type, 2015–2025
    Table 07: North America Antacids Market Size (US$ Mn) Forecast, By Distribution Channel, 2015–2025
    Table 08: North America Antacids Market Size (US$ Mn) Forecast, by Country, 2015–2025
    Table 09: Europe Antacids Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 10: Europe Antacids Market Size (US$ Mn) Forecast, by Formulation Type, 2015–2025
    Table 11: Europe Antacids Market Size (US$ Mn) Forecast, By Distribution Channel, 2015 and 2025
    Table 12: Europe Antacids Market Size (US$ Mn) Forecast, by Country, 2015–2025
    Table 13: Asia Pacific Antacids Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 14: Asia Pacific Antacids Market Size (US$ Mn) Forecast, by Formulation Type, 2015–2025
    Table 15: Asia Pacific Antacids Market Size (US$ Mn) Forecast, By Distribution Channel, 2015 and 2025
    Table 16: Asia Pacific Antacids Market Size (US$ Mn) Forecast, by Country, 2015–2025
    Table 17: Latin America Antacids Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 18: Latin America Antacids Market Size (US$ Mn) Forecast, by Formulation Type, 2015–2025
    Table 19: Latin America Antacids Market Size (US$ Mn) Forecast, By Distribution Channel, 2015–2025
    Table 20: Latin America Antacids Market Size (US$ Mn) Forecast, by Country, 2015–2025
    Table 21: Middle East and Africa Antacids Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 22: Middle East and Africa Antacids Market Size (US$ Mn) Forecast, by Formulation Type, 2015–2025
    Table 23: Middle East and Africa Antacids Market Size (US$ Mn) Forecast, By Distribution Channel, 2015 and 2025
    Table 24: Middle East and Africa Antacids Market Size (US$ Mn) Forecast, by Country, 2015–2025

    List of Figures

    Figure 01: Global Antacids Market Size (US$ Mn) Forecast, 2015–2025
    Figure 02: Market Value Share, By Drug Class (2016)
    Figure 03: Market Value Share, By Formulation Type (2016)
    Figure 04: Market Value Share By, Distribution Channel (2016)
    Figure 05: Market Value Share, By Region (2016)
    Figure 06: Porter’s Five Force Analysis
    Figure 07: Global Antacids Market Value Share Analysis, By Drug Class, 2016 and 2025
    Figure 08: Global Proton Pump Inhibitor Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
    Figure 09: Global H2 Antagonist Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
    Figure 10: Global Acid Neutralizer Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
    Figure 11: Antacids Market Attractiveness Analysis, By Drug Class
    Figure 12: Global Antacids Market Value Share Analysis, By Formulation Type, 2016 and 2025
    Figure 13: Global Antacids Tablet Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
    Figure 14: Global Antacids Liquids Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
    Figure 15: Global Antacids Powder Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
    Figure 16: Global Others Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
    Figure 17: Global Antacids Market Attractiveness Analysis, By Formulation Type
    Figure 18: Global Antacids Market Value Share Analysis, By Distribution Channel, 2016 and 2025
    Figure 19: Global Hospital Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
    Figure 20: Global Retail Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
    Figure 21: Global Others Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
    Figure 22: Global Antacids Market Attractiveness Analysis, By Distribution Channel
    Figure 23: Global Antacids Market Value Share, By Region, 2017 and 2025
    Figure 24: Global Antacids Market Attractiveness Analysis, By Region Type
    Figure 25: North America Antacids Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
    Figure 26: North America Antacids Market Attractiveness Analysis, By Country
    Figure 27: North America Antacids Market Value Share Analysis, By Drug Class, 2016 and 2025
    Figure 28: North America Antacids Market Value Share Analysis, By Formulation Type, 2016 and 2025
    Figure 29: North America Antacids Market Value Share Analysis, By Distribution Channel, 2016 and 2025
    Figure 30: North America Market Value Share Analysis, By Country, 2016 and 2025
    Figure 31: North America Antacids Market Attractiveness Analysis, By Drug Class
    Figure 32: North America Antacids Market Attractiveness Analysis, By Formulation Type 
    Figure 33: North America Antacids Market Attractiveness Analysis, By Distribution Channel
    Figure 34: Europe Antacids Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
    Figure 35: Europe Antacids Market Attractiveness Analysis, By Country
    Figure 36: Europe Market Value Share Analysis, By Drug Class, 2016 and 2025
    Figure 37: Europe Market Value Share Analysis, By Formulation Type, 2016 and 2025
    Figure 38: Europe Antacids Market Value Share Analysis, By Distribution Channel, 2016 and 2025
    Figure 39: Europe Market Value Share Analysis, By Country, 2016 and 2025
    Figure 40: Europe Antacids Market Attractiveness Analysis, By Drug Class
    Figure 41: Europe Antacids Market Attractiveness Analysis, By Formulation Type 
    Figure 42: Europe Antacids Market Attractiveness Analysis, By Distribution Channel
    Figure 43: Asia Pacific Antacids Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
    Figure 44: Asia Pacific Antacids Market Attractiveness Analysis, By Country
    Figure 45: Asia Pacific Market Value Share Analysis, By Drug Class, 2016 and 2025
    Figure 46: Asia Pacific Market Value Share Analysis, By Formulation Type, 2016 and 2025
    Figure 47: Asia Pacific Antacids Market Value Share Analysis, By Distribution Channel, 2016 and 2025
    Figure 48: Asia Pacific Market Value Share Analysis, By Country, 2016 and 2024
    Figure 49: Asia Pacific Antacids Market Attractiveness Analysis, By Drug Class
    Figure 50: Asia Pacific Antacids Market Attractiveness Analysis, By Formulation Type 
    Figure 51: Asia Pacific Antacids Market Attractiveness Analysis, By Distribution Channel
    Figure 52: Latin America Antacids Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
    Figure 53: Latin America Antacids Market Attractiveness Analysis, By Country
    Figure 54: Latin America Antacids Market Value Share Analysis, By Drug Class, 2016 and 2025
    Figure 55: Latin America Antacids Market Value Share Analysis, By Formulation Type, 2016 and 2025
    Figure 56: Latin America Antacids Market Value Share Analysis, By Distribution Channel, 2016 and 2025
    Figure 57: Latin America Market Value Share Analysis, By Country, 2016 and 2024
    Figure 58: Latin America Antacids Market Attractiveness Analysis, By Drug Class
    Figure 59: Latin America Antacids Market Attractiveness Analysis, By Formulation Type 
    Figure 60: Latin America Antacids Market Attractiveness Analysis, By Distribution Channel
    Figure 61: Middle East and Africa Antacids Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
    Figure 62: Middle East and Africa Antacids Market Attractiveness Analysis, By Country
    Figure 63: Middle East and Africa Market Value Share Analysis, By Drug Class, 2016 and 2025
    Figure 64: Middle East and Africa Market Value Share Analysis, By Formulation Type, 2016 and 2025
    Figure 65: Middle East and Africa Antacids Market Value Share Analysis, By Distribution Channel, 2016 and 2025
    Figure 66: Middle East and Africa Market Value Share Analysis, By Country, 2016 and 2025
    Figure 67: Middle East and Africa Antacids Market Attractiveness Analysis, By Drug Class
    Figure 68: Middle East and Africa Antacids Market Attractiveness Analysis, By Formulation Type 
    Figure 69: Middle East and Africa Antacids Market Attractiveness Analysis, By Distribution Channel
    Figure 70: AstraZeneca, Breakdown of Net Sales (%), by Region, 2016
    Figure 71: AstraZeneca, Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
    Figure 72: Bayer AG, Breakdown of Net Sales (%), by Region, 2016
    Figure 73: Bayer AG, Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
    Figure 74: Boehringer Ingelheim, Break down of Net Sales (%), by Region, 2016
    Figure 75: Boehringer Ingelheim, Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 76: Dr. Reddy’s, Breakdown of Net Sales (%), by Region, 2016
    Figure 77: Dr. Reddy’s, Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
    Figure 78: GlaxoSmithKline, Breakdown of Net Sales (%), by Region, 2016
    Figure 79: GlaxoSmithKline, Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
    Figure 80: Johnson & Johnson, Break down of Net Sales (%), by Region, 2016
    Figure 81: Johnson & Johnson, Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016
    Figure 82: Pfizer Inc., Breakdown of Net Sales (%), by Region, 2016 (%)
    Figure 83: Pfizer Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
    Figure 84: P&G, Breakdown of Net Sales (%), by Region, 2016
    Figure 85: P&G, Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
    Figure 86: Reckitt Benckiser, Breakdown of Net Sales (%), by Region, 2016
    Figure 87: Reckitt Benckiser, Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
    Figure 88: Sanofi, Breakdown of Net Sales (%), by Region, 2016
    Figure 89: Sanofi, Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
    Figure 90: Breakdown of Net Sales (%), by Region, 2016
    Figure 91: Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2016
    Figure 92: Takeda Pharmaceutical, Break down of Net Sales (%), by Region, 2016
    Figure 93: Takeda Pharmaceutical, Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
    Figure 94: Valeant Pharmaceuticals International, Inc., Break down of Net Sales (%), by Region, 2016
    Figure 95: Valeant Pharmaceuticals International, Inc., Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016

Copyright © Transparency Market Research, Inc. All Rights reserved